The ‘Barron’s Roundtable’ panelists discuss dividend stocks and reveal their stock picks.
Novo Nordisk’s blockbuster diabetes and weight loss-related drug Ozempic is set to see a price cut, according to President Donald Trump.
Trump said this week during a White House event on fertility treatments and drug pricing that the price reduction will come after swift negotiations with the drugmaker.
“They’ll be much lower,” Trump told reporters.
TRUMP’S QUEST TO REDUCE DRUG PRICES IS HEATING UP. BUT WILL HE BE ABLE TO DO IT?
Novo Nordisk is the maker behind Ozempic and Wegovy, which have the same active ingredient – semaglutide – but are approved for different uses. Ozempic was approved by federal health officials in 2017 and marketed for medical use in the treatment of type 2 diabetes with weight loss being a side effect of the drug.
Wegovy was approved four years later…



